ImmuCell Corporation Revenue 2011-2026 | ICCC

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue ImmuCell Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
27.6 M	26.5 M	17.5 M	18.6 M	19.2 M	15.3 M	13.7 M	11 M	10.4 M	9.54 M	10.2 M	7.6 M	6.01 M	5.39 M	5.11 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
27.6 M	5.11 M	13.6 M

Quarterly Revenue ImmuCell Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
5.51 M	6.44 M	8.07 M	-	6.01 M	5.47 M	7.26 M	-	5.4 M	3.53 M	3.45 M	-	4.8 M	3.86 M	6 M	-	5.15 M	4.54 M	4.11 M	-	3.72 M	2.97 M	15.3 M	-	2.97 M	2.71 M	4.41 M	-	2.15 M	3.01 M	2.88 M	-	2 M	1.75 M	3.54 M	-	144 K	332 K	158 K	-	157 K	295 K	193 K	-	283 K	214 K	126 K	-	288 K	211 K	105 K	-	221 K	133 K	-	-	214 K	139 K	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
15.3 M	105 K	3.03 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Alterity Therapeutics Limited ATHE	109 K	$ 5.15	15.21 %	$ 12.4 B	Australia
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Applied Therapeutics APLT	9.99 M	-	-	$ 8.42 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Aligos Therapeutics ALGS	2.19 M	$ 6.51	-2.54 %	$ 64.4 M	USA
Amphastar Pharmaceuticals AMPH	720 M	$ 22.92	0.17 %	$ 1.07 B	USA
Avenue Therapeutics ATXI	1.4 M	-	-52.27 %	$ 4.45 M	USA
BioNTech SE BNTX	482 M	$ 105.19	2.21 %	$ 27.2 B	Germany
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Can-Fite BioPharma Ltd. CANF	853 K	$ 3.0	-1.32 %	$ 4.94 M	Israel
Aeterna Zentaris AEZS	7.5 M	-	5.93 %	$ 314 M	Canada
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	236 M	$ 1.43	1.78 %	$ 368 M	USA
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
BeiGene, Ltd. BGNE	5.34 B	-	0.49 %	$ 251 B	Cayman-islands
Aquestive Therapeutics AQST	44.5 M	$ 4.24	-1.85 %	$ 453 M	USA
Arcutis Biotherapeutics ARQT	376 M	$ 24.47	-0.24 %	$ 3.11 B	USA
Burford Capital Limited BUR	330 M	$ 4.99	0.6 %	$ 804 M	Britain
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Autolus Therapeutics plc AUTL	75.4 M	$ 1.58	-1.25 %	$ 420 M	Britain
BioXcel Therapeutics BTAI	642 K	$ 1.2	4.35 %	$ 14.6 M	USA
Cabaletta Bio CABA	0.006	$ 3.31	-3.92 %	$ 333 M	USA
bluebird bio BLUE	29.5 M	-	-	$ 546 M	USA
Fennec Pharmaceuticals FENC	44.6 M	$ 6.73	-0.88 %	$ 192 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
CymaBay Therapeutics CBAY	31.1 M	-	-	$ 3.45 B	USA
Cidara Therapeutics CDTX	1.28 M	-	-	$ 1.41 B	USA
ChromaDex Corporation CDXC	129 M	-	-0.88 %	$ 598 M	USA